
Opinion|Videos|February 7, 2025
Decision-Making and Evidence Evaluation of Biosimilars
A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What characteristics (eg, cost, availability, accessibility, etc) of biosimilars are most important to your institution when deciding which agents to stock or keep on the formulary?
- What role do biosimilar switching studies play in this decision?
- In your experience, what are common barriers to implementing biosimilars at your institution?
- What strategies has your institution implemented to overcome the barriers to adopting biosimilars?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5





















